Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Erik Sparve"'
Autor:
Robert T. Keenan, S. Ohlman, Kenneth G. Saag, Alexander So, Michael H. Pillinger, Puja P. Khanna, Margareta Wikén, Ann‐Charlotte Åkerblad, Erik Sparve, Lisa Osterling Koskinen, Robert Terkeltaub
Publikováno v:
Arthritis & Rheumatology. 73:1533-1542
OBJECTIVE To evaluate the efficacy and safety of anakinra compared to triamcinolone in the treatment of gout flares. METHODS Patients for whom nonsteroidal antiinflammatory drugs and colchicine were not suitable treatments were enrolled in this multi
Autor:
María L. Couce, Mattias Rudebeck, Marco Spada, Erik Sparve, Allan M. Lund, Corinne De Laet, Carlo Dionisi-Vici, Ute Spiekerkoetter, Johan Szamosi, Anibh M. Das, Roshni Vara, Manuel Schiff
Publikováno v:
The Lancet Diabetes & Endocrinology. 9:427-435
Since the EU approval of nitisinone in 2005, prognosis for patients with hereditary tyrosinaemia type 1 has changed dramatically, with patients living with the disease now reaching adulthood for the first time in history. This study aimed to assess t
Publikováno v:
Journal of analytical toxicology. 44(9)
The use of oral fluid tests to detect drugs is of growing interest in various areas, including treatment centers, roadside and workplace testing. In this study, we investigated drug detection in oral fluid samples collected using a commercially avail
Publikováno v:
Drug Testing and Analysis. 10:1001-1008
Oral fluid sampling offers several advantages compared to other methods of detecting drugs in biological matrices due to its easy sampling procedure and simple supervision. Hence, the use of oral fluid for drug testing is increasing in workplaces and
Autor:
Pär Karlsson, Angelica Quartino, Tjerk Bueters, Kristina Claeson-Bohnstedt, Tina Olsson, Gunilla Huledal, Erik Sparve, Maria Lüttgen, Johanna Fälting, Chi-Ming Lee, Robert Alexander, Björn Paulsson, Justine Maltby, Jonathan Paraskos
Publikováno v:
Clinical Pharmacology in Drug Development. 3:396-405
Modulating deposition of Aβ-containing plaques in the brain may be beneficial in treating Alzheimer's disease. β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors have been shown to reduce Aβ in plasma and CSF in healthy voluntee
Autor:
Karin Tunblad, Robert Alexander, Angelica Quartino, Ahmad Al-Saffar, Jens Kågström, Michael D. B. Swedberg, Torbjorn Vik, Maria Lüttgen, Erik Sparve, Linnea Sjödin, Anna Teiling Gårdlund, Matthew Bridgland-Taylor, Alexander Bulgak, Johanna Fälting, Björn Paulsson, Chris Pollard
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 350(2)
Corrected QT interval (QTc) prolongation in humans is usually predictable based on results from preclinical findings. This study confirms the signal from preclinical cardiac repolarization models (human ether-a-go-go-related gene, guinea pig monophas
Publikováno v:
Journal of Clinical Psychopharmacology. 29:302-304
Autor:
Angelica, Quartino, Gunilla, Huledal, Erik, Sparve, Maria, Lüttgen, Tjerk, Bueters, Pär, Karlsson, Tina, Olsson, Jonathan, Paraskos, Justine, Maltby, Kristina, Claeson-Bohnstedt, Chi-Ming, Lee, Robert, Alexander, Johanna, Fälting, Björn, Paulsson
Publikováno v:
Clinical pharmacology in drug development. 3(5)
Modulating deposition of Aβ-containing plaques in the brain may be beneficial in treating Alzheimer's disease. β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors have been shown to reduce Aβ in plasma and CSF in healthy voluntee
Publikováno v:
Basicclinical pharmacologytoxicology. 105(5)
Triclosan is an antibacterial compound commonly used in cosmetics and personal care products for everyday use. As previously shown, triclosan is found in the plasma, urine and milk from large parts of different human populations. Recent studies have